|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor.
|
31460428 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining gene transfer of the melanoma-specific TRP2-TCR with Tet-IL-12 engineering revealed that temporal induction of IL-12 was essential to inhibit the growth of B16F10 melanoma tumors.
|
30723575 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
|
29355622 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By investigating compound FcγR-deficient mouse strains and by using immune cell type-specific cell ablation we show that the IgG antibody-mediated tumor protection elicited by MCMV-TRP2 mainly depends on FcγRI expression on macrophages, whereas FcγRIV plays only a modest role.
|
30034625 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8<sup>+</sup> T cells in the tumor microenvironment can be significantly enhanced.
|
30005865 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ImmunoMap analysis of the CD8 T-cell response to self-antigen (K<sup>b</sup>-TRP2) or to a model foreign antigen (K<sup>b</sup>-SIY) in naïve and tumor-bearing B6 mice showed differences in the T-cell repertoire of self- versus foreign antigen-specific responses, potentially reflecting immune pressure by the tumor, and also detected lymphoid organ-specific differences in TCR repertoires.
|
29263161 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas administration of the anti-TRP1 Ab alone reduced the frequency of these macrophages, the combination with a TLR agonist retained these cells in the tumor microenvironment.
|
30397036 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we introduce a versatile nanovaccine of liposomes-coated gold nanocages (Lipos-AuNCs) modified with DCs specific antibody aCD11c for targeted delivery of adjuvant MPLA and melanoma antigen peptide TRP2 to promote the activation and maturation of DCs, and enhance tumor specific T lymphocytes responses.
|
28992509 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice.
|
28273716 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vivo study showed that mice having received TRP2 loaded implants had delayed tumour growth for 3days compared to groups having received no TRP2.
|
28104440 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that conditional ablation in cone photoreceptors of Ran-binding protein-2 (Ranbp2), a cell context-dependent pleiotropic protein linked to neuroprotection, familial necrotic encephalopathies, acute transverse myelitis and tumor-suppression, promotes early electrophysiological deficits, subcellular erosive destruction and non-apoptotic death of cones, whereas rod photoreceptors undergo cone-dependent non-autonomous apoptosis.
|
23818861 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DC-shA20-FAP-TRP2 vaccination enhanced tumor infiltration of CD8-positive T cells, and induced antigen-spreading resulting in potent antitumor activity.
|
24349329 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test for functionality, we adoptively transferred TCR-engineered T cells into mice bearing B16 melanomas and observed delayed growth of established tumors with pmel-1 TCR engineered CD8+ T cells and significant tumor regression with TRP-1 TCR transduced CD4 T cells.
|
21499127 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preparation and characterization of recombinant protein ScFv(CD11c)-TRP2 for tumor therapy from inclusion bodies in Escherichia coli.
|
17027283 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FISH showed ALK-RANBP2 fusion in this tumor.
|
17656252 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth was reduced and survival enhanced in mice immunized with the combination of TRP2-P2/Agonist and TYR/Agonist compared to mice receiving reverse peptide or vehicle.
|
17986862 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
More than 25% of tumour cells showed strong protein expression in 13, 34, 85 and 96% of GBM samples for gp100, TRP-2, EGFRvIII and IL-13Ralpha2, respectively.
|
17004103 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TRP-2 protein expression was detected in GBM cells and tumor tissues by Western blot and immunohistochemistry.
|
12843792 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression was screened in an array containing RNA-derived cDNA from 241 tumor and corresponding matched normal tissues from individual patients. p270 deficiency was observed at a higher overall frequency than BRG1 deficiency, but all tissues were not equally affected.
|
15382044 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, proteasome inhibitors preventing the generation of the MART-1/Melan-A(27-35) immunodominant melanoma tumor-associated antigen (TAA) promoted detectable presentation of TRP-2(476-484) epitope in HLA-A2.1(+) and TRP-2(+) tumor lines, as witnessed by cytokine release by specific T-cell clones.
|
10861482 |
2000 |